AU Patent

AU2014271320B2 — Tenofovir alafenamide hemifumarate

Assigned to Gilead Sciences Inc · Expires 2017-02-23 · 9y expired

What this patent protects

A hemifumarate form of 9-[(R>2-[[(S)-[[(S>1-(isopropoxycarbonyl)ethyl] amino] phenoxyphosphinyl]m (tenofovir alafenamide), and antiviral therapy using tenofovir 5 alafenamide hemifumarate (e.g., anti-HTV and anti-HBV therapies). Formula (I). 0 WOPh H

USPTO Abstract

A hemifumarate form of 9-[(R>2-[[(S)-[[(S>1-(isopropoxycarbonyl)ethyl] amino] phenoxyphosphinyl]m (tenofovir alafenamide), and antiviral therapy using tenofovir 5 alafenamide hemifumarate (e.g., anti-HTV and anti-HBV therapies). Formula (I). 0 WOPh H

Drugs covered by this patent

Patent Metadata

Patent number
AU2014271320B2
Jurisdiction
AU
Classification
—
Expires
2017-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.